Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, 3902 Leavenworth Street, Omaha, NE, USA.
Biomed Res Int. 2013;2013:830837. doi: 10.1155/2013/830837. Epub 2013 Nov 11.
As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.
作为导致失明的主要原因之一，年龄相关性黄斑变性（AMD）一直是眼科临床研究的重点。在过去的十年中，研究人员的注意力范围从了解血管内皮生长因子（VEGF）在血管生成级联中的作用，到为视网膜血管疾病开发新的治疗方法。雷珠单抗和阿柏西普等抗 VEGF 药物已成为越来越成熟的治疗方法，并已取代了早期的治疗方法，如激光光凝或光动力疗法。许多其他处于早期临床试验阶段的新型治疗药物已显示出有前途的结果。本文旨在简要回顾新生血管性 AMD 的现有治疗方法，然后重点介绍目前处于不同开发阶段的有前途的新疗法。
